drugset
drugset / Trial / NCT01327313

A Study of EMD525797 in Solid Tumor Patients in Japan

NCT01327313 ↗

Phase 1 Completed 27 enrolled Merck KGaA, Darmstadt, Germany
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objectives are to assess the safety and tolerability of single and repeated doses of EMD525797, and characterize Pharmacokinetics (PK). The secondary objectives are to investigate the immunogenicity and Progressive disease (PD), and to assess the anti-tumor activity of EMD525797.

Timeline

Start
2011-01
Primary completion
2012-07
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Abituzumab Monoclonal antibody 250 mg Intravenous
Subject Abituzumab Monoclonal antibody 500 mg Intravenous
Subject Abituzumab Monoclonal antibody 1000 mg Intravenous
Subject Abituzumab Monoclonal antibody 1500 mg Intravenous

Indications

cancer